SS-31 Elamipretide: Mitochondrial Research Peptide Profile
SS-31 elamipretide is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it interacts with cardiolipin to support mitochondrial architecture and electron transport chain efficiency. In preclinical and translational research settings, SS-31 has become one of the most studied mitochondria-targeting compounds, offering researchers a tool for investigating how mitochondrial respiration influences cellular health across multiple organ systems.
Mitochondrial Dysfunction and the Role of SS-31
A wide body of research has examined how mitochondrial dysfunction contributes to conditions ranging from cardiomyopathy to neurodegenerative states. The mitochondrial membrane is central to ATP synthesis, and disruptions to its integrity are associated with oxidative stress, reduced mitochondrial respiration, and eventual cell death. SS-31 is designed to concentrate at the inner mitochondrial membrane, stabilizing cardiolipin and preserving electron transport chain architecture. Research shows that this mechanism significantly affects cellular energy production and reactive oxygen species generation in experimental models.
Studies in animal models have documented improvements in mitochondrial function following SS-31 administration, including enhanced ATP output, reduced mitochondrial swelling, and normalization of membrane potential. These findings have made SS-31 a subject of considerable interest for research into age-related mitochondrial decline and metabolic disorders.
SS-31 in Clinical Trials
SS-31 (elamipretide) has progressed into multiple clinical trials, making it one of the few mitochondria-targeting peptides to reach human research phases. Clinical investigations have explored its potential in conditions associated with impaired mitochondrial energy metabolism. Trials in subjects with heart failure have evaluated functional outcomes, while studies in rare inherited mitochondrial diseases have assessed safety and tolerability profiles. These controlled research studies provide a framework for understanding how SS-31 interacts with dysfunctional mitochondria in human tissues.
Researchers note that the peptide is generally well tolerated in research populations, with injection site reactions being the most commonly reported finding across study cohorts. Data from early-phase trials suggest dose-dependent changes in exercise tolerance and cardiac output metrics, findings that continue to be explored in ongoing investigations.
Accelerated Approval Pathway and Barth Syndrome
SS-31 has attracted regulatory attention for its potential application in Barth syndrome, a rare X-linked mitochondrial disorder characterized by cardioskeletal myopathy, neutropenia, and abnormal cardiolipin remodeling. Because Barth syndrome patients have a well-characterized defect in cardiolipin metabolism, SS-31’s mechanism of action—stabilizing cardiolipin at the inner mitochondrial membrane—is mechanistically aligned with the pathophysiology of the disease. This scientific rationale contributed to discussions around an accelerated approval pathway for the compound, with Stealth BioTherapeutics (the developer, who pursued it under the brand name Forzinity) pursuing regulatory engagement based on biomarker and functional endpoints.
Research in Barth syndrome models has demonstrated measurable improvements in mitochondrial respiration, cardiac remodeling metrics, and exercise capacity, lending further translational relevance to the compound’s mechanism.
Heart Failure Research Applications
Preclinical and early clinical research has explored SS-31 in the context of heart failure, a condition in which mitochondrial dysfunction is a well-established contributor to reduced cardiac contractility and output. In animal models of ischemia-reperfusion injury, SS-31 treatment has been associated with smaller infarct areas, improved left ventricular ejection fraction, and reduced markers of oxidative damage. Translational research in adult and pediatric patients with heart failure has begun to examine whether these preclinical signals correspond to measurable clinical benefit.
Researchers studying cardiac remodeling have noted that the peptide’s effects appear to extend beyond acute injury protection, with longer-term studies showing potential for slowing structural changes in failing myocardium. Stealth BioTherapeutics conducted pivotal research programs targeting this indication, contributing substantial data to the scientific literature.
Mechanism: Targeting the Inner Mitochondrial Membrane
The tetrapeptide structure of SS-31 (D-Arg-2’6′-dimethylTyr-Lys-Phe-NH2) confers a net positive charge that facilitates selective accumulation within mitochondria, driven by the large negative membrane potential of the inner mitochondrial membrane. Once localized at the inner membrane, SS-31 interacts directly with cardiolipin, a unique phospholipid essential for the proper folding and function of respiratory chain supercomplexes. By stabilizing cardiolipin interactions with cytochrome c, SS-31 preserves electron transport chain efficiency and reduces electron leakage—the primary source of mitochondrial superoxide generation. This antioxidant mechanism operates upstream of most conventional antioxidants, acting at the site of ROS production rather than scavenging radicals after formation.
Electron microscopy studies in SS-31-treated mitochondria show preserved cristae ultrastructure compared to untreated controls, reinforcing the view that the peptide exerts structural as well as functional effects on the organelle. These features have positioned SS-31 as a reference compound in mitochondria-targeting pharmacology research.
Preclinical Research Models
SS-31 has been studied across a broad range of preclinical models, including rodent models of cardiac ischemia, genetic mitochondrial disease, renal ischemia-reperfusion injury, skeletal muscle atrophy, and neurodegenerative pathology. In each setting, experimental data consistently indicate that SS-31 treatment preserves mitochondrial respiration, reduces ROS generation, and supports cellular viability under conditions of metabolic stress. Key findings include reductions in apoptotic signaling, improvements in ATP-to-ADP ratios, and attenuation of inflammatory cytokine cascades linked to mitochondrial damage-associated molecular patterns.
In aged rodent models, SS-31 has been reported to partially reverse age-related mitochondrial dysfunction, raising interest in its potential application for geroscience research. These studies have examined mitochondrial function in skeletal muscle, heart, and kidney tissues, documenting measurable improvements in respiration rates and exercise performance in treated animals.
SS-31 Research Availability and Sourcing
For qualified researchers investigating mitochondrial biology, SS-31 elamipretide is available as a research-grade compound for in vitro and in vivo laboratory use. Purity and formulation consistency are critical for reproducible experimental outcomes. Research-grade SS-31 is available for laboratory procurement from Iron Peak Peptides, a supplier supporting the research community with quality-tested peptide compounds.
Researchers should verify compound purity via certificate of analysis documentation before experimental use. Standard characterization methods include HPLC purity analysis and mass spectrometry confirmation of molecular weight.
Summary of SS-31 Research Findings
SS-31 elamipretide represents a mechanistically distinct approach to modulating mitochondrial function through direct engagement with the inner mitochondrial membrane and cardiolipin. Its progression from basic biochemistry research into clinical trials—including studies in Barth syndrome and heart failure—reflects the strength of the preclinical evidence base and the scientific community’s interest in mitochondria-targeting therapeutics. Key areas of ongoing research include cardiac remodeling, mitochondrial respiration in aging tissues, and rare genetic disorders of mitochondrial metabolism.
As with all research peptides, SS-31 is intended exclusively for scientific study under appropriate research conditions. All use should comply with institutional guidelines and applicable regulations governing research compound handling and experimentation.
Research Use Only
All information provided on this page is intended strictly for scientific research and educational purposes. SS-31 elamipretide is a research compound not approved for human therapeutic use outside of regulated clinical trial settings. This content does not constitute medical advice, and no information herein should be interpreted as a recommendation for any clinical application. Researchers should adhere to all institutional, regulatory, and ethical guidelines governing the use of research peptides.